A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

Cleary, James M. ; Lima, Caio Max S. Rocha ; Hurwitz, Herbert I. ; Montero, Alberto J. ; Franklin, Catherine ; Yang, Jianning ; Graham, Alison ; Busman, Todd ; Mabry, Mack ; Holen, Kyle ; Shapiro, Geoffrey I. ; Uronis, Hope

Investigational new drugs, 2014-10, Vol.32 (5), p.937-945 [Periódico revisado por pares]

New York: Springer US

Texto completo disponível